China NMPA accepts for review GSK’s Nucala NDA to treat patients with chronic obstructive pulmonary disease: London, UK Friday, February 21, 2025, 09:00 Hrs [IST] GSK plc announ ...

New research led by scientists at La Jolla Institute for Immunology (LJI) reveals the workings of a human antibody called mAb ...

Scientists have discovered a potentially greener way to produce a crucial industrial chemical used to make many everyday ...

The treatment landscape of Inflammatory Bowel Disease (IBD) has undergone a significant transformation over the past two ...

Eli Lilly wants to take big swings in Alzheimer’s, ALS, chronic pain and other difficult diseases after its success in ...

In December 2023, through the development efforts of CRISPR Therapeutics and Vertex Pharmaceuticals, their decades-long ...

Another healthcare stock came across our desk during the mid-week session after it was announced that Piper Sandler initiated ...

Pembrolizumab is a checkpoint inhibitor that binds to the protein PD-1 on T cells to help them recognize and attack invaders.

In part 4 of our interview, we learn more about nipocalimab’s safety profile and how this investigative agent might address ...

This story contains spoilers for “Apple Cider Vinegar.” Early in the new Netflix miniseries “Apple Cider Vinegar,” the ...

Evolucumab (Repatha) and alirocumab (Praluent) are injectable monoclonal antibodies. They have been joined by inclisiran ...